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To the Editor,
A 19-year-old male presented in 1999 with anemia, increased
inflammatory parameters and knee complaints, based on dif-
fuse-type giant cell tumor (DGCT). In 2010, a low femoral
amputation was performed after several functional joint spar-
ing surgeries and a short unsuccessful period of imatinib
400mg once daily (OD) therapy [1]. Histopathology showed
destructive DGCT with secondary changes due to imatinib
treatment, but no signs of malignancy.
Four years later, he presented with fever, sweating, ano-
rexia, weight loss, palpitations and anemia. FDG-positron
emission tomography (PET)-computed tomography (CT) scan
showed new pulmonary lesions and mediastinal lymphaden-
opathy. A cytological lymph node biopsy proved metastastic
DGCT. Imatinib 400mg OD and predisolone 30mg OD were
started. No other immune-modulating therapy has been
administered. Two months after start of imatinib and prednis-
olone, his clinical condition deteriorated with weight loss,
fever and inflammation (Table 1). FDG-uptake showed
increased metabolic activity of metastases. To prevent atelec-
tasis, the highly metabolically active right hilar metastasis
was irradiated (30Gy in 10 fractions; Figure 1(a)). During
radiotherapy, his condition rapidly deteriorated with high
fevers, profound anemia, hypoalbumenia, decreased
sodium, hyperglycemia and pulmonary infection (Table 1).
Unexpectedly, within two weeks after completing radiotherapy,
he clinically improved and his inflammatory laboratory values
decreased (Table 1). FDG-PET-CT showed response of the
right irradiated hilar lesion, volumetric and metabolic
response of left-sided non-irradiated pulmonary metastases
and an increase of uptake in one mediastinal lymph node
(Figure 1(b) and (c)). This phenomenon is called abscopal
effect. It persisted for six months, after which he progressed
and died from disease three months later.
Discussion
The abscopal effect induced by radiotherapy is rare and is
mostly reported in tumor types considered immunogenic
such as melanoma, but has to our knowledge never been
described in mesenchymal malignancies [2]. The immune sys-
tem has been proposed as the key component of this absco-
pal effect [3]. Local radiotherapy induces cell death and
release of immunogenic factors, leading to host immune
responses. Damage-associated molecular patterns trigger
dendritic cells, resulting in improved antigen presentation to
T cells [2,4]. Pharmacological modification of the abscopal
effect has been suggested for immune checkpoint inhibitors
and granulocyte-macrophage colony-stimulating factor [4–7].
Here we report a patient with malignant DGCT with
marked inflammatory symptoms and laboratory parameters,
who demonstrated a systemic benefit from local radiotherapy
by an abscopal effect. Tenosynovial giant cell tumors are rare
Table 1. Laboratory results.
Parameter (normal range)
Before start of
radiotherapy
Day 5 of radiotherapy
(10 3 Gy)
Last day of
radiotherapy
3 weeks after completing
radiotherapy
Hemoglobulin (8.4–10.8mmol/l) 5.1 5.1a 5.8 6.7
Leukocytes (4.0–11.0 109/l) 17.4 15.1 13.2 16.8
Platelets (150–400 109/l) 811 609 567 445
Neutrophils (2–7.5 109/l) 12.7 12.4 11.4
Lymphocytes (1–3.5 109/l) 2.4 0.6 0.5
Monocytes (0.3–1.0 109/l) 2.3 2.0 1.3
Sodium (135–145mmol/l) 134 129 127 135
Albumin (35–50 g/l) 13 10 10 17
CRP (<10mg/ml) 200 225 82
aErythrocyte transfusion was administered after this measurement. CRP: C-reactive protein.
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mesenchymal lesions that arise from the synovial lining of
articular spaces, bursal sacs, and tendon sheaths. The diffuse-
type is an aggressive multifocal proliferation of synovial-like
mononuclear cells with inflammatory infiltrates. Metastases of
DGCT are extremely rare. The current treatment strategies
have recently been reviewed [8]. The inflammatory nature
and the observed abscopal effect plea for considering immu-
notherapeutic approaches in this disease.
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Figure 1. Computed tomography (CT) (left column), FDG-positron emission tomography (PET) (middle column) and combined FDG-PET-CT (right column) before
the start (pre) and after completion (post) of radiotherapy. (a) showing high uptake of FDG in the right hilar diffuse-type giant cell tumor metastasis before the start
of radiotherapy and impressive decrease in FDG-uptake, corresponding with metabolic response 3 weeks after completion of radiotherapy. Abscopal effect in the
left pulmonary metastases (b) and mediastinal lymphadenopathy (c), showing a volume response on CT and metabolic response on FDG-PET-CT in the pulmonary
lesions as well as increased uptake in a mediastinal lymph node on FDG-PET-CT, in keeping with an immunological reaction.
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